Infectious Disease Diagnostics Market to Double in Value, Projected to Reach USD 43.2 Billion by 2034 at a 7.2% of CAGR

Infectious Disease Diagnostics Market 

The global infectious disease diagnostics market, valued at USD 21.5 billion in 2024, is set to grow steadily, reaching an anticipated USD 43.2 billion by 2034. With a projected CAGR of 7.2% over the next decade, the market is driven by the increasing need for rapid, accurate diagnostics in managing infectious diseases worldwide.

Several factors are contributing to the growth of this market:

1. Rising Incidence of Infectious Diseases: The global prevalence of infectious diseases, including emerging and re-emerging infections, underscores the need for efficient diagnostics to ensure timely treatment.
2. Advancements in Diagnostic Technology: Innovations in molecular diagnostics, PCR, and immunoassay technologies are enabling faster and more accurate detection of pathogens, improving diagnostic efficiency.
3. Growing Awareness and Focus on Early Detection: As healthcare systems emphasize prevention and early intervention, demand for reliable infectious disease diagnostics has increased significantly.
4. Government Initiatives and Funding: Support from governments and health organizations worldwide to combat infectious diseases is fueling advancements in diagnostics and expanding market access.
5. Increased Demand for Point-of-Care Testing: The shift towards point-of-care testing has enhanced accessibility to diagnostics in both developed and developing regions, supporting more effective disease management.

As the healthcare industry continues to prioritize effective infection control, the infectious disease diagnostics market is expected to play a critical role in managing public health, offering solutions to meet growing global health demands.

POCT will continue to gain traction, particularly in resource-limited areas and during outbreaks where access to centralized laboratories is limited. The integration of AI and machine learning algorithms into diagnostic platforms will streamline data analysis, interpretation, and decision-making processes.

AI-powered diagnostic tools will enhance accuracy, efficiency, and scalability, revolutionizing infectious disease diagnostics and surveillance.

Molecular diagnostics, including PCR and NGS-based assays, will remain at the forefront of infectious disease diagnostics. The ability of these tests to detect pathogens with high sensitivity and specificity makes them indispensable in clinical practice and public health settings.

As the global burden of infectious diseases continues to rise, there will be a growing demand for molecular diagnostic tests for early detection and monitoring.

With the ongoing threat of emerging infectious diseases and the rise of antimicrobial resistance, there will be increased emphasis on developing diagnostic tests for newly identified pathogens and drug-resistant strains. Public health efforts will prioritize surveillance, early detection, and containment of emerging threats, driving investment in novel diagnostic solutions.

Competitive Landscape of Infectious Disease Diagnostics Industry

Leading companies in the infectious disease diagnostics market are employing several strategies to foster growth. These include investing in research and development to innovate new diagnostic technologies expanding their product portfolios to offer a comprehensive range of testing solutions.

In addition, they are forging strategic partnerships and collaborations with other industry players or healthcare institutions, enhancing market presence through mergers and acquisitions, and focusing on geographic expansion to tap into emerging markets.

Additionally, players are prioritizing customer education and support to increase awareness and adoption of their diagnostic products and services, ultimately driving market growth and profitability.

• In March 2024, Diasorin (FTSE MIB: DIA) received 510(k) approval from USA Food and Drug Administration (FDA) to launch the LIAISON PLEX® platform and its first respiratory test panel, the LIAISON PLEX® Respiratory Flex Assay.
• In April 2024, BD (Becton, Dickinson and Company), a global leader in medical technology, received USA Food and Drug Administration (FDA) 510(k) approval for its Respiratory Viral Panel (RVP) for its BD MAX System. This instant diagnosis system can identify and differentiate influenza A, SARS-CoV-2, influenza B, and Respiratory Syncytial Virus.

Get the Comprehensive Full Report Now

Infectious Disease Diagnostics Market by Category

By Product:

In terms of product, the market encompasses assays & reagents, instruments, and software.

By Disease Type:

Based on disease types, the market is categorized into hepatitis, human immunodeficiency virus, influenza, and others.

By Technology:

The technology segment comprises immunodiagnostics, clinical microbiology, polymerase chain reaction, and next-generation sequencing.

By Region:

As per region, the industry is divided into North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe, and the Middle East and Africa.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube